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• 心筋の興奮収縮連関ECC, Ca signaling
• 強心薬 cardiotonic agents











































臨床的には 1) 心原性肺水腫pulmonary edema，
2) 心原性ショックshock及び 3) 慢性左室不全の
急性増悪acute exacerbationの三状態を含む”
























(LV filling pressure: preload)


Natural history of congestive heart failure (CHF).
Once left ventricular systolic dysfunction is present, it usually progresses, albeit not predictably. 
As left ventricular dysfunction progresses and symptoms increase, mortality rate increase and the 
process becomes inexorable. Myocyte loss and fibrosis become irreversible. An effective 






















a/b = Ejection fraction （EF 駆出率 %）
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a/b = Ejection fraction （EF駆出率 %）




















強心薬 cardiotonic agents 
Catecholamines, Digitalis, Ca sensitizer
（補）PDE3阻害薬やピモベンダンの有用性




































Above are two cross sections of left ventricle from a patient with severe 
long-standing hypertension. There is severe left ventricular 
hypertrophy. The hypertrophy is designated concentric because the left 
ventricle and septum are of approximately equal thickness. The walls of 
the ventricles are thickened, but the cavity size is decreased. Left 
ventricular hypertrophy is a response to chronically elevated afterload 










Dilated cardiomyopathy. Histology demonstrating variable myocyte
hypertrophy and interstitial fibrosis (collagen is highlighted as blue in this 









There is granular 
mural thrombus at 
the apex of the left 
ventricle (on the right in 
this apical four-chamber 
view).
図4-2, 4-13参照
New Engl J Med 1999; 341:577-585 
The baroreceptor-mediated increase in sympathetic 
tone that occurs with ventricular dysfunction has 
several consequences, including 
(1) increased myocardial contractility,
(2) tachycardia, 
(3) arterial vasoconstriction and thus 
(4) increased cardiac afterload, and 
(5) venoconstriction with increased cardiac preload. 
β-Adrenergic receptors in the heart either are 
down-regulated (β1-adrenergic receptors) or have 
abnormalities in signal-transduction activity that 
effectively uncouple them from effector mechanisms 
(β1- and β2-adrenergic receptors). 
Increased local and circulating concentrations of 
noradrenaline (NAd) may contribute to myocyte 
hypertrophy, either directly through stimulation of α1- and 
β-adrenergic receptors or secondarily by activating the 
renin-angiotensin-aldosterone (R-A-A) system.  NAd is 
directly toxic to myocardial cells, an effect mediated 
through Ca overload, the induction of apoptosis, or both. 
Patients with plasma NAd concentrations greater than 800 
pg /ml (4.7 nmol/l) have a one-year survival of less than 40 
percent, unless there has been a reversible insult.
NAd -induced death of myocytes can be prevented by 
concomitant nonselective β-adrenergic blockade or 
combined β-and α-adrenergic blockade. 
New Engl J Med 1999; 341:577-585 
In the past, β-adrenergic blockade was thought to 
be contraindicated in patients with heart failure 
(HF). However, if patients can tolerate short-term 
β-adrenergic blockade, ventricular function 
subsequently improves. 
In randomized, placebo-controlled clinical trials, the 
nonselective β-adrenergic antagonist carvedilol
and the selective β1-adrenergic antagonists 
bisoprolol, and metoprolol decreased morbidity 
and mortality in patients with HF. 
LVEF
(%)
Time-dependent effects of metoprolol on LVEF in patients with HF.
left ventricular ejection fraction




























Control Candesartan (AT1 blocker)
Left ventricular remodeling after 
myocardial infarction (MI).
左室リモデリング手術






































































































































IC50 = 0.3 nM
経口投与不可能 経口投与可能
candesartan cilexetil
       (TCV-116)
















[Ca2+]i上昇機構;  <Ca transient>
DHP受容体 (Ca2+ channel; L type, Ca class) 
Ca2+流入増強 by A kinase (cAMP)










































































SRCaポンプ SR Ca pump (75%)
Ca2+ uptake増強 by A kinase 図2-19 
細胞膜Caポンプ plasma membrane Ca pump
Na-Ca交換体 Na-Ca exchanger  (20%)
図4-16










TnI : Ca感受性低下 by A kinase (cAMP); 速い弛緩
Positive lusitropic
心筋収縮の制御 （まとめ）
Control of Normal Cardiac Contractility
A. Sensitivity of the Contractile Proteins to Ca: 
Troponin C, I ＜Ca sensitizer＞
B. The Amount of Ca Released From the SR
C. The Amount of Ca Stored in the SR
D. The Amount of Trigger Ca: Ca channel
E. Activity of the Na-Ca Exchanger 





























































































Stimulation of β1-adrenergic receptors
Gs protein coupling
Activation of adenylyl cyclase
Increase in cyclic AMP
Activation of A kinase
Positive chronotropic



























































Structure of the sarcomere of cardiac muscle;
mutations in hypertrophic cardiomyopathy
Structure of the sarcomere of cardiac muscle, 
highlighting proteins in which mutations cause defective 
contraction, hypertrophy, and myocyte disarray in 
hypertrophic cardiomyopathy. The frequency of a 
particular gene mutation is indicated as a percentage; 
most common are mutations in b-myosin heavy chain. 
Normal contraction of the sarcomere involves myosin-
actin interaction initiated by calcium binding to troponin 
C and transducing through I, T and a-tropomyosin. Actin 
stimulates ATPase activity in the myosin head and 
produces force along the actin filaments. Myosin-binding 
protein C modulates contraction. (From Spirito P, et al: The 










































































Digitoxin = Tri-digitoxose + Digitoxigenin




Bufotoxin = Suberoylarginine 








a) 陽性変力作用 positive inotorpic
b) 活動電位持続時間（APD）の短縮
c) Ca過負荷（Ca2+ overload）






























Schematic representation of the heart and normal 














(L type Ca2+ channel)
Na+ channel
Figure 13-5. Electrocardiographic record showing digitalis-
induced bigeminy. The complexes marked NSR are normal 
sinus rhythm beats; an inverted T wave and depressed ST 
segment are present. The complexes marked PVB are 
premature ventricular beats. 
盆状降下
Lead V4 at rest (top) & after 4.5min of exercise (bottom). 
There is 0.3 mV of horizontal ST-segment depression, 















強心薬 cardiotonic agents 
Catecholamines, Digitalis, Ca sensitizer
（補）PDE3阻害薬やピモベンダンの有用性
静注用心不全治療薬の特徴
（安村良男：呼吸と循環 Vol52 No9 2004）より、改変
収縮性 前負荷 後負荷 意義
DA ↑ ↑ ↑ 血圧を上げる
Dobutamine ↑ ↑ → 心拍出量を増やす
Milrinone ↑ ↓ ↓ EDPを下げ、心拍出量を増やす
hANP, 
Nicorandil












CaV: 電位依存性L型Ca2+チャネル -P （Ca2+流入↑、[Ca2+]i↑）
NCX: Na/Ca亣換体
PLB: ホスホランバン-P（SRCaポンプ機能↑、Caトランジェント短縮、弛緩亢進）
RyR: Ca2+遊離チャネル-P （Ca2+遊離↑ 、[Ca2+]i↑）
Tm: トロポミオシン










































1.9 2.1 2.3 2.5
陽性変力作用
弛緩亢進作用
収縮期
拡張期
サルコメア長
補助人工心臓(VAS) 磁気浮上型左心補助人工心臓
磁気浮上型遠心血液ポンプ
＜渦巻きポンプの一種＞
電源、
コントローラー
大動脈
左心室
渦巻きポンプの羽根車
Volute pump
心不全の重症度からみた薬物治療指針
（ 日本循環器学会：『慢性心不全治療ガイドライン（2005年改訂版）』p.26，図4より）
http://www.j-
circ.or.jp/guideline/pdf/JCS20
10_matsuzaki_h.pdf
